Overview

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

Status:
Active, not recruiting

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

A retrospective chart review of an open-label trial of low-dose ketamine administered to front-line Healthcare workers who were identified as experiencing acute stress disorder due to the COVID-19 Pandemic.

Phase:

Phase 4

Details

Lead Sponsor:

Limbic Medical

Collaborator:

Enovex Pharmacy

Treatments:

Ketamine